Amunix Raises $73 Million in Series A Financing Led by Omega Funds
March 04, 2020 07:00 ET
|
Amunix Pharmaceuticals, Inc.
-- Harnessing clinically validated prodrug technology to advance novel pipeline of T cell engager and cytokine agents that are selectively activated in the tumor microenvironment -- -- Proprietary T...
Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology
January 10, 2020 07:00 ET
|
Amunix Pharmaceuticals, Inc.
Amunix to receive $40 million in upfront payment and may receive up to $1.5 billion in development and sales milestonesRoche to utilize XTEN, Amunix’s clinically validated therapeutic half-life...
Amunix Pharmaceuticals Announces the Appointment of Dr. Maninder Hora as Chief Technical Operations Officer
August 27, 2019 07:03 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
June 26, 2019 07:05 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
Amunix Expands Executive Team with Appointment of Dr. Mika Derynck as CMO, Dr. Darcy Mootz as CBO, and Yvonne Li as SVP of Finance
May 14, 2019 08:05 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on the discovery and development of novel protein therapeutics,...
Amunix announces report by Bioverativ on unprecedented half-life obtained in patients treated with a novel, long-acting FVIII utilizing Amunix’s XTEN® technology
May 29, 2018 07:00 ET
|
Amunix Operating Inc
MOUNTAIN VIEW, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- Amunix Operating Inc. is pleased to report that Bioverativ (a Sanofi company) has announced preliminary Phase 1/2a safety and pharmacokinetic...
Amunix announces XTEN® and ProTIA technology licensing agreement with Celgene
February 20, 2018 07:00 ET
|
Amunix Operating Inc
MOUNTAIN VIEW, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Amunix Operating Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapeutics,...
Amunix CEO to deliver keynote address on ProTIA, Amunix’s novel immuno-oncology technology, at the Biologics & Biosimilars Congress Europe (March 2018)
February 13, 2018 07:00 ET
|
Amunix Operating Inc
MOUNTAIN VIEW, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Amunix Operating Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapeutics,...
Bioverativ announces FDA acceptance of Investigational New Drug Application for BIVV001, a novel, long-acting FVIII hemophilia therapeutic utilizing Amunix XTEN® half-life extension technology
June 14, 2017 07:00 ET
|
Amunix Operating Inc
MOUNTAIN VIEW, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Amunix Operating Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has accepted Bioverativ’s (NASDAQ:BIVV)...